ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1301

The Tumor Necrosis Factor Stimulated Gene-6 Promoter Reporter Can Monitor The Disease Activity In Rheumatoid Arthritis

Mathijs G.A. Broeren1, Eline A. Vermeij1, Onno J. Arntz2, Miranda B. Bennink1, Emma Sterken1, Calin Popa2, Tim L. Jansen3, Wim B. van den Berg4 and Fons A.J. Van de Loo5, 1Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Rheumatology, Radboud UMC, Nijmegen, Netherlands, 4Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, 5Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: biomarkers and serologic tests, Diagnostic Tests, Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose: An important step in the optimal personalized treatment of rheumatoid arthritis (RA) patients, is the accurate assessment of disease activity, disease progression and therapy response. The quantification of biomarkers has been proposed to monitor these processes, but no single biomarker has proven to be sufficiently reliable for this purpose. Instead of measuring the quantity of a biomarker, we focus on the biomarker promoter activity to take into account the complex interplay between stimulating and inhibiting factors.

The TNF stimulated gene 6 (TSG-6) encodes a 35-kDa secretory glycoprotein that is induced in fibroblasts, chondrocytes, synovial cells and mononuclear cells by proinflammatory cytokines. Large amounts of TSG-6 protein were found in synovial fluid of patients with RA. In this study, we set out to use the TSG-6 promoter to develop a promoter-reporter construct to monitor disease activity in RA.

Methods: Arthritis was induced in DBA1/J mice by immunization with bovine collagen-type II (CIA), or by intra-articular injection of 5 µg Streptococcal Cell Wall (SCW). Microarray experiments were performed on 15 CIA samples, 20 human end-point RA synovium samples and 6 control synovium samples. The TSG-6 promoter (-499 to +63) was cloned in a lentiviral vector (LV) encoding firefly luciferase. Murine 3T3 cells were cultured and stimulated with 1% mouse serum or 10% human serum for 6 hours. Luciferase activity was measured using BrightGlo reagent.

Results: TSG-6 was upregulated in arthritic CIA joints and expression correlated with disease severity.  It was also upregulated ~6-fold in 20 human end-point RA synovium samples, compared to 6 non-arthritic synovium samples (P=0.01).

Subsequently, we studied the disease-inducibility of the TSG-6 promoter by developing a lentiviral construct in which the isolated TSG-6 promoter controls the expression of a luciferase reporter transgene (TSG6-luc). We infected mice with the TSG6-luc promoter reporter and induced SCW arthritis. The expression peaked at day 7 (19-fold compared to naive mice), indicating the disease-responsiveness at full blown synovitis.

Next, we transduced murine 3T3 cells with the LV TSG6-luc construct and incubated the cells with  serum from mice with increasing severity of collagen induced arthritis. The response of the promoter correlated significantly with the macroscopically assessed disease severity (R2 0.47, P<0.0001) and with their circulating levels of the neutrophil chemokine KC (R2 0.31, P=0.002), the functional homologue of human IL-8. In addition, serum from human RA patients showed a significantly higher activation of the TSG6-luc construct, compared to serum from healthy patients (P=0.001).

An important characteristic of a successful reporter is a reduced signal after successful treatment. We tested this by comparing the response to serum from diseased arthritic mice to serum from mice that were successfully treated with Enbrel. Serum from Enbrel treated mice showed a significantly lower activation of the TSG-6 promoter, compared to serum from untreated mice.

Conclusion: The TSG-6 promoter reporter might be a valuable tool to monitor disease progression in RA patients.


Disclosure:

M. G. A. Broeren,
None;

E. A. Vermeij,
None;

O. J. Arntz,
None;

M. B. Bennink,
None;

E. Sterken,
None;

C. Popa,
None;

T. L. Jansen,
None;

W. B. van den Berg,
None;

F. A. J. Van de Loo,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-tumor-necrosis-factor-stimulated-gene-6-promoter-reporter-can-monitor-the-disease-activity-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences